149 related articles for article (PubMed ID: 11349879)
1. Thalidomide as an anti-angiogenic agent in relapsed gliomas.
Short SC; Traish D; Dowe A; Hines F; Gore M; Brada M
J Neurooncol; 2001 Jan; 51(1):41-5. PubMed ID: 11349879
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK
J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas.
Ruiz J; Case D; Enevold G; Rosdhal R; Tatter SB; Ellis TL; McQuellon RP; McMullen KP; Stieber VW; Shaw EG; Lesser GJ
J Neurooncol; 2012 Feb; 106(3):611-7. PubMed ID: 21870118
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB
J Clin Oncol; 2003 Jun; 21(12):2299-304. PubMed ID: 12805330
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
6. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
Groves MD; Puduvalli VK; Chang SM; Conrad CA; Gilbert MR; Tremont-Lukats IW; Liu TJ; Peterson P; Schiff D; Cloughesy TF; Wen PY; Greenberg H; Abrey LE; DeAngelis LM; Hess KR; Lamborn KR; Prados MD; Yung WK
J Neurooncol; 2007 Feb; 81(3):271-7. PubMed ID: 17031561
[TBL] [Abstract][Full Text] [Related]
7. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme.
Turner CD; Chi S; Marcus KJ; MacDonald T; Packer RJ; Poussaint TY; Vajapeyam S; Ullrich N; Goumnerova LC; Scott RM; Briody C; Chordas C; Zimmerman MA; Kieran MW
J Neurooncol; 2007 Mar; 82(1):95-101. PubMed ID: 17031553
[TBL] [Abstract][Full Text] [Related]
9. Reirradiation and lomustine in patients with relapsed high-grade gliomas.
Arcicasa M; Roncadin M; Bidoli E; Dedkov A; Gigante M; Trovò MG
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):789-93. PubMed ID: 10098434
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.
Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR
J Neurooncol; 2001 Aug; 54(1):31-8. PubMed ID: 11763420
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
Chan JK; Manuel MR; Ciaravino G; Cheung MK; Husain A; Teng NN
Gynecol Oncol; 2006 Dec; 103(3):919-23. PubMed ID: 16828852
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide as second-line chemotherapy for relapsed gliomas.
Trent S; Kong A; Short SC; Traish D; Ashley S; Dowe A; Hines F; Brada M
J Neurooncol; 2002 May; 57(3):247-51. PubMed ID: 12125988
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma.
Morabito A; Fanelli M; Carillio G; Gattuso D; Sarmiento R; Gasparini G
Oncol Rep; 2004 Jan; 11(1):93-5. PubMed ID: 14654909
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Darcy KM; Abulafia O; Hanjani P; Pearl ML; Rubin SC; Rose PG; Small L; Benbrook DM
Gynecol Oncol; 2012 Nov; 127(2):356-61. PubMed ID: 22796461
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
Seystahl K; Wiestler B; Hundsberger T; Happold C; Wick W; Weller M; Wick A
Eur Neurol; 2013; 69(2):95-101. PubMed ID: 23182901
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Vestermark LW; Larsen S; Lindeløv B; Bastholt L
Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
